BACKGROUND: For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). METHODS: Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 microg) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV. They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF. RESULTS: A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 6B, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. CONCLUSIONS: In patients with CLL, the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF. In all patients, reactogenicity was minor. (c) 2008 American Cancer Society.
RCT Entities:
BACKGROUND: For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharidepneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). METHODS:Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 microg) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV. They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSF. RESULTS: A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 6B, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. CONCLUSIONS: In patients with CLL, the response to pure polysaccharidepneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF. In all patients, reactogenicity was minor. (c) 2008 American Cancer Society.
Authors: C Y Chan; D C Molrine; S George; N J Tarbell; P Mauch; L Diller; R C Shamberger; N R Phillips; A Goorin; D M Ambrosino Journal: J Infect Dis Date: 1996-01 Impact factor: 5.226
Authors: Daniel M Musher; Adriana M Rueda-Jaimes; Edward A Graviss; Maria C Rodriguez-Barradas Journal: Clin Infect Dis Date: 2006-09-01 Impact factor: 9.079
Authors: K Pauksen; A Linde; V Hammarström; J Sjölin; J Carneskog; G Jonsson; G Oberga; H Engelmann; P Ljungman Journal: Clin Infect Dis Date: 2000-02 Impact factor: 9.079
Authors: I Sklenar; G Schiffman; V Jønsson; G Verhoef; H Birgens; M Boogaerts; A Ferrant; B E Christensen; H Hasle; A Drivsholm Journal: Oncology Date: 1993 Nov-Dec Impact factor: 2.935
Authors: Eli Muchtar; Amber B Koehler; Michael J Johnson; Kari G Rabe; Wei Ding; Timothy G Call; Jose F Leis; Saad S Kenderian; Suzanne R Hayman; Yucai Wang; Paul J Hampel; Matthew A Holets; Heather C Darby; Susan L Slager; Neil E Kay; Congrong Miao; Jennifer Canniff; Jennifer A Whitaker; Myron J Levin; D Scott Schmid; Richard B Kennedy; Adriana Weinberg; Sameer A Parikh Journal: Am J Hematol Date: 2021-11-05 Impact factor: 13.265
Authors: Marcin Pasiarski; Barbara Sosnowska-Pasiarska; Ewelina Grywalska; Agnieszka Stelmach-Gołdyś; Artur Kowalik; Stanisław Góźdź; Jacek Roliński Journal: Clin Interv Aging Date: 2019-10-09 Impact factor: 4.458
Authors: S Lanfranconi; F Locatelli; S Corti; L Candelise; G P Comi; P L Baron; S Strazzer; N Bresolin; A Bersano Journal: J Cell Mol Med Date: 2009-12-08 Impact factor: 5.310